Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Baxter/Alpha Aralast Launch Will Ease Bayer Prolastin Supply Pressure

  • News

Executive Summary

Baxter/Alpha Therapeutics' Aralast alpha-1 proteinase inhibitor launch should ease ongoing supply pressures on Bayer's Prolastin

You may also be interested in...



Zemaira Clears FDA; Aventis Behring Seeks Distribution Partner

Aventis Behring is looking externally to boost the sales force for its Zemaira alpha-1 proteinase inhibitor

Zemaira Clears FDA; Aventis Behring Seeks Distribution Partner

Aventis Behring is looking externally to boost the sales force for its Zemaira alpha-1 proteinase inhibitor

CBER’s Long Goodbye: Biologics Approval Time Jumps To 30 Months In 2002

The average approval time for new biologic therapeutics and vaccines in 2002 was 30.1 months, an 11-month increase from 2001

Table

View full table

Tags:
Latest Headlines

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

See All
UsernamePublicRestriction

Register

PS041072

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By